Overview

Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind (Investigator and study subject), placebo controlled multiple dose sequential ascending dose study that will enroll up to 47 male and female subjects with type 2 diabetes mellitus (T2DM) in up to four cohorts.
Phase:
Phase 2
Details
Lead Sponsor:
PhaseBio Pharmaceuticals Inc.